AVDL
Avadel Pharmaceuticals plc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IE
$21.64
+0.00%Year over year
Reported trailing growth
- Revenue
- +79.9%
- EBITDA
- +116.7%
- EBIT
- +107.1%
- EPS
- +100.0%
- Free cash flow
- +142.8%
- Operating cash flow
- +143.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +504.8%
- EBITDA
- +76.1%
- EBIT
- +69.2%
- Net income
- +69.5%
- EPS
- +74.5%
- Free cash flow
- +63.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025